Investigative safety science as a competitive advantage for Pharma.
about
Enrichment with wood blocks does not affect toxicity assessment in an exploratory toxicology model using Sprague-Dawley ratsThe Utility of Gene Expression Profiling from Tissue Samples to Support Drug Safety Assessments.Predicting the Drug Safety for Traditional Chinese Medicine through a Comparative Analysis of Withdrawn Drugs Using Pharmacological Network.Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing.Stratification of paracetamol overdose patients using new toxicity biomarkers: current candidates and future challenges.Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon?
P2860
Investigative safety science as a competitive advantage for Pharma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Investigative safety science as a competitive advantage for Pharma.
@en
type
label
Investigative safety science as a competitive advantage for Pharma.
@en
prefLabel
Investigative safety science as a competitive advantage for Pharma.
@en
P2093
P2860
P1476
Investigative safety science as a competitive advantage for Pharma.
@en
P2093
Andre Cordier
David J Heard
Dominique Brees
Francois Pognan
Jonathan Moggs
Michael Kammüller
Michael Merz
Michele Leonard
Page Bouchard
Pierre Moulin
P2860
P304
P356
10.1517/17425255.2012.693914
P407
P577
2012-07-07T00:00:00Z